WallStSmart

DarioHealth Corp (DRIO)vs10X Genomics Inc (TXG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

10X Genomics Inc generates 2914% more annual revenue ($638.78M vs $21.19M). TXG leads profitability with a -3.5% profit margin vs -192.2%. DRIO earns a higher WallStSmart Score of 23/100 (F).

DRIO

Avoid

23

out of 100

Grade: F

Growth: 2.7Profit: 4.0Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: -5.45

TXG

Avoid

20

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 1.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DRIOUndervalued (+9.9%)

Margin of Safety

+9.9%

Fair Value

$12.21

Current Price

$7.30

$4.91 discount

UndervaluedFair: $12.21Overvalued
TXGUndervalued (+68.1%)

Margin of Safety

+68.1%

Fair Value

$60.02

Current Price

$52.03

$7.99 discount

UndervaluedFair: $60.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DRIO2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Return on EquityProfitability
100.5%10/10

Every $100 of equity generates 101 in profit

TXG1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Areas to Watch

DRIO4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$71.17M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-17.3%2/10

Revenue declined 17.3%

TXG4 concerns · Avg: 3.3/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-2.8%2/10

ROE of -2.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DRIO

The strongest argument for DRIO centers on Price/Book, Return on Equity.

Bull Case : TXG

The strongest argument for TXG centers on Debt/Equity.

Bear Case : DRIO

The primary concerns for DRIO are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : TXG

The primary concerns for TXG are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

TXG carries more volatility with a beta of 2.04 — expect wider price swings.

TXG is growing revenue faster at -2.6% — sustainability is the question.

TXG generates stronger free cash flow (25M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DRIO scores higher overall (23/100 vs 20/100). TXG offers better value entry with a 68.1% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DarioHealth Corp

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

DarioHealth Corp. The company is headquartered in New York, New York.

Visit Website →

10X Genomics Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Want to dig deeper into these stocks?